As big pharmaceutical companies run into roadblocks in discovering new treatments, they are turning to AI startups for assistance.
Large pharmaceutical companies are partnering with AI startups to develop new drugs and therapeutics.
Artificial intelligence could expedite the drug discovery process by finding new molecular compounds faster than traditional methods. AI may also improve predictions for the outcomes of new drugs, potentially boosting the likelihood of success through each stage of the drug development pipeline.
Pharma giants like Pfizer are collaborating with startups like XtalPi, a Massachusetts-based startup backed by Google, Sequoia Capital China, and Tencent Holdings. The company will use the startup’s AI software for molecular modeling.
